First Thing, Daily Maverick's flagship newsletter

Join the 230 000 South Africans who read First Thing newsletter.

We'd like our readers to start paying for Daily Maverick

More specifically, we'd like those who can afford to pay to start paying. What it comes down to is whether or not you value Daily Maverick. Think of us in terms of your daily cappuccino from your favourite coffee shop. It costs around R35. That’s R1,050 per month on frothy milk. Don’t get us wrong, we’re almost exclusively fuelled by coffee. BUT maybe R200 of that R1,050 could go to the journalism that’s fighting for the country?

We don’t dictate how much we’d like our readers to contribute. After all, how much you value our work is subjective (and frankly, every amount helps). At R200, you get it back in Uber Eats and ride vouchers every month, but that’s just a suggestion. A little less than a week’s worth of cappuccinos.

We can't survive on hope and our own determination. Our country is going to be considerably worse off if we don’t have a strong, sustainable news media. If you’re rejigging your budgets, and it comes to choosing between frothy milk and Daily Maverick, we hope you might reconsider that cappuccino.

We need your help. And we’re not ashamed to ask for it.

Our mission is to Defend Truth. Join Maverick Insider.

Support Daily Maverick→
Payment options

India's Zydus Cadila seeks approval for its 3-dose COVI...



India’s Zydus Cadila seeks approval for its 3-dose COVID vaccine

A man after receiving a shot of the Covid-19 vaccine during the vaccination drive for sports persons in Bangalore, India, on 10 June 2021. (Photo: EPA-EFE / JAGADEESH NV)
By Reuters
01 Jul 2021 0

BENGALURU, July 1 (Reuters) - Indian drugmaker Zydus Cadila said on Thursday it has applied for emergency use approval of its three-dose COVID-19 vaccine that showed efficacy of 66.6% in an interim study and could become the second home-grown shot if regulators consent.

By Anuron Kumar Mitra

Although coronavirus infections have dropped from a devastating peak in April and May that strained healthcare facilities, experts have warned of a third wave, saying widespread vaccination is one of the best pandemic defences.

Zydus’ vaccine “will certainly help in ramping up India’s overall vaccination drive as it would be the fifth approved,” Prashant Khadayate, a pharmaceutical industry analyst at GlobalData said.

Zydus said the efficacy result is based on an interim analysis of a late-stage trial of more than 28,000 volunteers nationwide, including nearly 1,000 subjects in the age group of 12 to 18.

The drugmaker said it was evaluating a two-dose regimen for the shot.

If approved, ZyCoV-D will be the world’s first DNA vaccine, Zydus said, as it makes use of a portion of the genetic code – DNA or RNA – in the SARS-CoV-2 virus to stimulate an immune response against its spike protein.

DNA vaccines differ from other approved COVID-19 shots, which are based on new mRNA technology such as in those from Pfizer and Moderna, and established technology like viral vectors, as with AstraZeneca.

Zydus, which aims to produce up to 120 million doses annually, said its study coincided with the peak of India’s second wave of infections and affirmed its efficacy against new mutants, especially the Delta variant.

It did not, however, disclose its efficacy against those variants. (Reporting by Anuron Kumar Mitra in Bengaluru, Editing by Sherry Jacob-Phillips)

Information pertaining to Covid-19, vaccines, how to control the spread of the virus and potential treatments is ever-changing. Under the South African Disaster Management Act Regulation 11(5)(c) it is prohibited to publish information through any medium with the intention to deceive people on government measures to address COVID-19. We are therefore disabling the comment section on this article in order to protect both the commenting member and ourselves from potential liability. Should you have additional information that you think we should know, please email [email protected]


Please peer review 3 community comments before your comment can be posted